Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS ( C ontrolled H igh-Risk A VONEX ® (interferon beta-1a) M ultiple Sclerosis (MS) P revention Study I n O ngoing N eurologic S urveillance) study, an open label follow-up to CHAMPS ( C ontrolled H igh Risk Subjects A VONEX M S P revention S tudy). Based on the CHAMPS study,
AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting. ...
report in Medical News TodayLabels: Avonex
